Sponsors (82)
Makes immediate expensing the default for qualifying research and experimental expenditures and keeps an elective amortization option; removes mandatory foreign R&E amortization.
Official title: To amend the Internal Revenue Code of 1986 to restore the deduction for research and experimental expenditures.
Introduced March 10, 2025 by Ron Estes · Last progress March 10, 2025
The bill lets businesses immediately expense R&E (boosting near‑term cash flow and simplifying cross‑border treatment) at the cost of retroactive adjustments, added compliance burdens, and reduced flexibility/greater future income variability for some taxpayers.
Businesses (including small businesses) can immediately deduct research & experimental (R&E) expenses paid or incurred in the year, reducing taxable income and improving near‑term cash flow and tax liabilities.
Removes the mandatory foreign R&E amortization rule and generally makes domestic and foreign R&E eligible for immediate expensing, simplifying tax treatment and reducing compliance complexity for firms with cross-border R&E.
Preserves an elective amortization alternative for capitalized R&E that isn’t eligible for depreciation, giving some taxpayers a choice if expensing is not optimal for their situation.
Taxpayers who previously capitalized foreign R&E under the prior mandatory amortization rules may face retroactive tax adjustments, amended returns, and increased compliance costs for years after 2021 due to the change in treatment.
Allowing immediate expensing can reduce the smoothing of taxable income over time, increasing variability in future taxable income and complicating longer‑term tax planning for businesses.
Once a taxpayer adopts the expensing method they generally must stick with it unless the IRS consents to a change, which limits accounting-method flexibility and could lock taxpayers into a choice that later proves suboptimal.
Based on analysis of 2 sections of legislative text.
Allows businesses to immediately expense research and experimental (R&E) expenditures in the year paid or incurred, while keeping an elective amortization alternative for certain capitalized research amounts; it removes the prior mandatory amortization rule that specifically required foreign research expenditures to be amortized. Conforming changes adjust interactions with the R&D tax credit and related code cross-references. The changes apply to taxable years beginning after December 31, 2021.